Patents Represented by Attorney, Agent or Law Firm Ron K. Levy
-
Patent number: 6790823Abstract: Methods and compositions for the prevention and treatment of cardiovascular disease is described. Administration of osteoprotegerin (OPG) in a pharmaceutical composition prevents and treats atherosclerosis and associated cardiovascular diseases.Type: GrantFiled: April 23, 1998Date of Patent: September 14, 2004Assignee: Amgen Inc.Inventors: Scott Simonet, Ildiko Sarosi
-
Patent number: 6764836Abstract: There are disclosed Interleukin-15 Receptor (IL-15R) proteins, DNAs and expression vectors encoding IL-15R, and processes for producing IL-15R as products of recombinant cell cultures.Type: GrantFiled: March 10, 2003Date of Patent: July 20, 2004Assignee: Immunex CorporationInventors: Dirk M. Anderson, Judith G. Giri
-
Patent number: 6743778Abstract: The present invention concerns therapeutic agents that mimic the activity of Apo-AI amphipathic helix peptide. In accordance with the present invention, the compounds of the invention comprise: a. a Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domain, preferably the amino acid sequence of SEQ ID NO: 7, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques mentioned above; and b. a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle, preferably an Fc domain, is covalently attached to the Apo-AI amphipathic helix peptide or Apo-AL amphipathic helix peptide-mimetic domain. The vehicle and the Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domain may be linked through the N- or C-terminus of the Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domain, as described further below.Type: GrantFiled: April 23, 2001Date of Patent: June 1, 2004Assignee: Amgen Inc.Inventor: Tadahiko Kohno
-
Patent number: 6723701Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3 and BDNF, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.Type: GrantFiled: December 19, 2000Date of Patent: April 20, 2004Assignee: Amgen Inc.Inventors: Thomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young
-
Patent number: 6677136Abstract: The present invention concerns therapeutic agents that antagonize the activity of glucagon. In accordance with the present invention, the compounds of the invention comprise: a. a glucagon antagonist domain, preferably the amino acid sequence of SEQ ID NO: 7, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques; and b. a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the glucagon antagonist domain. The vehicle and the glucagon antagonist domain may be linked through the N- or C-terminus of the glucagon antagonist domain. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.Type: GrantFiled: May 2, 2001Date of Patent: January 13, 2004Assignee: Amgen Inc.Inventors: William S. Marshall, Kevin Lee Stark
-
Patent number: 6664107Abstract: A mammal lacking expression of particular CD45 isoform in certain cells of the immune system is provided. The mammal may optionally contain a transgene encoding the CD45RO isoform. Also provided are methods of using these mammals.Type: GrantFiled: February 2, 1994Date of Patent: December 16, 2003Assignee: Ontario Cancer Institute, University Health NetworkInventors: Tak Wah Mak, Kenji Kishihara
-
Patent number: 6660843Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, E. coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.Type: GrantFiled: October 22, 1999Date of Patent: December 9, 2003Assignee: Amgen Inc.Inventors: Ulrich Feige, Chuan-Fa Liu
-
Patent number: 6656508Abstract: The present invention relates to sustained-release formulations using alginate gel beads and methods thereof.Type: GrantFiled: April 17, 1997Date of Patent: December 2, 2003Assignee: Amgen Inc.Inventors: Merrill Seymour Goldenberg, Alice C. Beekman
-
Patent number: 6649604Abstract: Selected novel substituted pyrimidinone and pyridone compounds are effective for prophylaxis and treatment of diseases, such as TNF-&agr;, IL-1&bgr;, IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: GrantFiled: April 23, 2002Date of Patent: November 18, 2003Assignee: Amgen Inc.Inventors: Ulrike D. Spohr, Michael J. Malone, Nathan B. Mantlo, Jeffrey A. Zablocki
-
Patent number: 6645990Abstract: Selected novel urea compounds are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: GrantFiled: February 15, 2002Date of Patent: November 11, 2003Assignee: Amgen Inc.Inventors: Benny C. Askew, Frenel F. De Morin, Andrew Hague, Ellen Laber, Aiwen Li, Gang Liu, Patricia Lopez, Rana Nomak, Vincent Santora, Christopher Tegley, Kevin Yang
-
Patent number: 6632638Abstract: Disclosed are methods for improving the solubility of a protein of interest produced recombinantly by expressing the protein of interest as a fusion protein with Uracil DNA glycosylase inhibitor (UGI).Type: GrantFiled: November 17, 2000Date of Patent: October 14, 2003Assignee: Amgen, Inc.Inventors: Marshall Snavely, Lana Klionsky
-
Patent number: 6613544Abstract: The present invention discloses a novel secreted polypeptide, termed Osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding Osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind Osteoprotegerin, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.Type: GrantFiled: December 22, 1995Date of Patent: September 2, 2003Assignee: Amgen Inc.Inventors: William J. Boyle, David L. Lacey, Frank J. Calzone, Ming-Shi Chang
-
Patent number: 6610698Abstract: Selected novel substituted pyrimidine compounds are effective for prophylaxis and treatment of diseases, such as TNF-&agr;, IL-1&bgr;, IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: GrantFiled: April 3, 2002Date of Patent: August 26, 2003Assignee: Amgen, Inc.Inventors: Ulrike D. Spohr, Michael J. Malone, Nathan B. Mantlo
-
Patent number: 6605634Abstract: The present invention comprises a new class of novel aryl and heteroaryl substituted fused pyrrole compounds useful for the prophylaxis and treatment of diseases or conditions, such as TNF-&agr;, IL-1&bgr;, IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of inflammation and other maladies, such as pain and diabetes, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.Type: GrantFiled: June 18, 2002Date of Patent: August 12, 2003Assignee: Amgen, Inc.Inventors: Jeffery A. Zablocki, Eugene Tarlton, Jr., James P. Rizzi, Nathan B. Mantlo
-
Patent number: 6589758Abstract: The invention relates to the three-dimensional structure of a crystal of a kinase enzyme complexed with a ligand. The three-dimensional structure of a protein kinase-ligand complex is disclosed. The invention also relates to methods of preparing such crystals. Kinase-ligand crystal structures wherein the ligand is an inhibitor molecule are useful for providing structural information that may be integrated into drug screening and drug design processes. Thus, the invention also relates to methods of using the crystal structure of kinase enzyme-ligand complexes for identifying, designing, selecting, or testing inhibitors of kinase enzymes, such inhibitors being useful as therapeutics for the treatment or modulation of i) diseases; ii) disease symptoms; or iii) the effect of other physiological events mediated by kinases; having one or more kinase enzymes involved in their pathology.Type: GrantFiled: May 21, 2001Date of Patent: July 8, 2003Assignee: Amgen Inc.Inventor: Xiaotian Zhu
-
Patent number: 6586398Abstract: The present invention broadly relates to the field of protein modification, and, more specifically, the attachment of water soluble polymers to novel erythropoietin stimulating protein (NESP).Type: GrantFiled: April 7, 2000Date of Patent: July 1, 2003Assignee: Amgen, Inc.Inventors: Olaf Kinstler, Colin Gegg, Aimee Freeman, Thomas Boone
-
Patent number: 6583154Abstract: There are provided compounds, compositions and methods of use thereof in the modulation of feeding behavior, obesity, diabetes, cancer (tumor), inflammatory disorders, depression, stress related disorders, Alzheimer's disease and other disease conditions.Type: GrantFiled: August 16, 2000Date of Patent: June 24, 2003Assignee: Amgen Inc.Inventors: Mark Henry Norman, Clarence R. Hurt, Ning Chen, Christopher H. Fotsch, Nianhe Han, Tracy J. Jenkins, Longbin Liu, Ofir A. Moreno
-
Patent number: 6565841Abstract: Methods and compositions for pulmonary delivery of chemically modified G-CSF, and pegylated proteins are disclosed.Type: GrantFiled: March 8, 1993Date of Patent: May 20, 2003Assignee: Amgen, Inc.Inventors: Ralph Niven, Colin G Pitt
-
Patent number: 6552170Abstract: Compounds are disclosed having the general formula R1-X-R2, wherein R1 and R2 are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R1 and R2 may be the same or different. Preferred R1 and R2 groups are TNF inhibitors.Type: GrantFiled: June 14, 1994Date of Patent: April 22, 2003Assignee: Amgen Inc.Inventors: Robert C. Thompson, Michael T. Brewer, Tadahiko Kohno
-
Patent number: 6541033Abstract: The present invention relates generally to the development of pharmaceutical compositions which provide for sustained release of biologically active polypeptides. More specifically, the invention relates to the use of thermosensitive, biodegradable hydrogels, consisting of a block copolymer of poly(d,l- or l-lactic acid)(PLA) or poly(lactide-co-glycolide)(PLGA) and polyethylene glycol (PEG), for the sustained delivery of biologically active agents, such as leptin.Type: GrantFiled: June 30, 1998Date of Patent: April 1, 2003Assignee: Amgen Inc.Inventor: Subodh Shah